Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.
--------
Question: Context: To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis. Three multicenter, randomized, double-masked, placebo-controlled, dose-ranging phase III studies: SHIELD, INSURE, and ENDURE. A total of 118 patients with Behcet's uveitis (SHIELD study); 31 patients with active, noninfectious, non-Behcet's uveitis (INSURE study); and 125 patients with quiescent, noninfectious, non-Behcet's uveitis (ENDURE study) were enrolled. After an initial subcutaneous (s.c.) loading phase in each treatment arm, patients received s.c. maintenance therapy with secukinumab 300 mg every 2 weeks (q2w), secukinumab 300 mg monthly (q4w), or placebo in the SHIELD study; secukinumab 300 mg q2w, secukinumab 300 mg q4w, secukinumab 150 mg q4w, or placebo in the INSURE study; or secukinumab 300 mg q2w, secukinumab 300 mg q4w, secukinumab 150 mg q4w, or placebo in the ENDURE study. Reduction of uveitis recurrence or vitreous haze score during withdrawal of concomitant immunosuppressive medication (ISM). Other end points included best-corrected visual acuity, ISM use (expressed as a standardized ISM score), and safety outcomes. After completion or early termination of each trial, there were no statistically significant differences in uveitis recurrence between the secukinumab treatment groups and placebo groups in any study. Secukinumab was associated with a significant reduction in mean total post-baseline ISM score (P = 0.019; 300 mg q4w vs. placebo) in the SHIELD study. Likewise, secukinumab was associated with a greater median reduction in ISM score versus placebo in the INSURE study, although no statistical analysis of the difference was conducted because of the small sample size. Overall, there was no loss in visual acuity reported in any treatment group during follow-up in all 3 studies. According to descriptive safety statistics, the frequencies of ocular and nonocular adverse events seemed to be slightly higher among secukinumab groups versus placebo across the 3 studies. The primary efficacy end points of the 3 studies were not met. The secondary efficacy data from these studies suggest a beneficial effect of secukinumab in reducing the use of concomitant ISM. 
 Question: Which molecule is targeted by a monoclonal antibody Secukinumab?

Answer: interleukin-17a


Question: Context: In America, when the eighth graders leave the middle school, they are often worried about moving to the high school. It is a hard time for them, but it can be an exciting one as well. To make it easier, students need to get familiar with their school. Even though they've done this already in the middle school, it's still important to find where their classrooms are. Most schools take students to the high school for a visit at the end of their eighth grade year. And, most schools also have a freshman speech for parents and students before the first year begins. Sometimes the main office will give away a map of the school. This can help students and parents to find different places in the school. One way to know your high school more and make new friends is to join a club or play a sport. Schools often offer chances to join different clubs and sports. Fall activities begin in August before the first day of school. If you are not interested in sports, there are clubs for any interest, such as drama, dance, chess, photography, community service, etc. These clubs allow students from different grades. By joining an activity, students can find new friendships, not to mention improving their chances in future college applications . The school office will have a list of activities offered at the school and information on how to join them. What's more, to have a great start to a high school year, students can write down some of their worries, and ask for help from teachers and school workers. 
 Question: When do many schools take students to visit their new high school?

Answer: at the end of their eighth grade year


Question: Context: The Avi Chai Foundation is a private foundation endowed in 1984 by Zalman Bernstein, a well-known successful investor and founder of Sanford Bernstein. 
 Question: Who is the founder of Avi Chai Foundation?

Answer:
zalman bernstein